ChristopherJosephLaingMD
Radiology • Sacramento, CAInterventional Neuroradiology, Vascular & Interventional Radiology
Physician
Dr. Laing is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3161 L St
Sacramento, CA 95816Phone+1 916-732-7777
Education & Training
University of Illinois College of Medicine at PeoriaFellowship, Vascular and Interventional Radiology, 2007 - 2008
The MetroHealth System/Case Western Reserve UniversityResidency, Radiology-Diagnostic, 2002 - 2007
University of Tennessee Health Science Center College of MedicineClass of 2002
Certifications & Licensure
OH State Medical License 2002 - 2026
CA State Medical License 2008 - 2025
IL State Medical License 2007 - 2017- American Board of Radiology Interventional Radiology and Diagnostic Radiology
Publications & Presentations
PubMed
- 100 citationsRandomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.Robert C.G. Martin, Charles R. Scoggins, Marshall T. Schreeder, William S. Rilling, Christopher J. Laing
Cancer. 2015-10-15 - 113 citationsAcute gastrointestinal bleeding: emerging role of multidetector CT angiography and review of current imaging techniques.Christopher J. Laing, Terrence Tobias, David I. Rosenblum, Wade L. Banker, Lee Tseng
Radiographics. 2007-07-01 - Double-Balloon Catheter-Mediated Transarterial Chemotherapy Delivery in a Swine Model: A Mechanism Recruiting the Vasa Vasorum for Localized Therapies.Khashayar Farsad, Paula M Novelli, Christopher Laing, Ripal T Gandhi, Jacob Cynamon
Journal of Vascular and Interventional Radiology. 2024-07-01
Press Mentions
GenScript and Duke-NUS Announce Notice of Allowance for “Surrogate Virus Neutralization Technology”June 23rd, 2021- Duke-NUS and GenScript Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization TestJune 21st, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
